Patrizia Giannatempo

5PUBLICATIONS
53CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 18, 2025
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to Abemaciclib.

Amedeo Nuzzo, Marco Barella, Melanie Claps

|Jul 08, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.

Mimma Rizzo, Andrey Soares, Shilpa Gupta

|Jun 20, 2025
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.

Valentina Tateo, Joep J de Jong, Antonio Cigliola

|Nov 17, 2021
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group).

Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo

|Sep 02, 2020
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas.

Camillo Porta, Patrizia Giannatempo, Mimma Rizzo

Pageof 1

Frequent Collaborators

3 joint publications

Andrea Necchi

2 joint publications

Mimma Rizzo

2 joint publications

Sebastiano Buti

2 joint publications

Maurizio Colecchia